Dr. John Cush RheumNow
2 years 3 months ago
FDA has approved risankizumab (Skyrizi) to treat adults with moderately to severely active ulcerative colitis (UC), making it the IL-23 inhibitor approved for UC. Approval is based on two large phase 3 clinical trials (COMMAND, INSPIRE) https://t.co/JWX5SBEvT5 https://t.co/MrMFmOyQqa
Dr. John Cush RheumNow
2 years 3 months ago
JAK inhibitors have been used as adjunctive therapy to reduce flammation arising with checkpoint inhibitor use in cancer (Hodgkins, Lung CA), using itacitinib w/ pembrolizumab or ruxolitinib & nivolumab improved trial outcomes https://t.co/hMmrifhiNN https://t.co/LPHc5GyOaA
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Dr. John Cush RheumNow
2 years 3 months ago
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria
https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC
Dr. John Cush RheumNow
2 years 3 months ago
Artificial Intelligence: Detection of CPPD on Hand Radiographs
Dr. Antoni Chan interviews Dr. Thomas Hugle about abstract OP0112 presented at Eular 2024 in Vienna, Austria. https://t.co/jQrwKXuaDc https://t.co/Ecv69wvHxA
Dr. John Cush RheumNow
2 years 3 months ago
In patients with bio-naïve r-axSpA, Ixekizumab treatment for 16 weeks decreased erosion scores and increased backfill scores, particularly in the IXE Q2W group, consistent with rapid tissue repair #EULAR2024 Abst OP0046 @RheumNow https://t.co/bVYjnBqpaf
Dr. John Cush RheumNow
2 years 3 months ago
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/3Tp777HVTD https://t.co/PRrjm65nFK
Dr. John Cush RheumNow
2 years 3 months ago
"AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007
A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.
Dr. John Cush RheumNow
2 years 3 months ago
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
Dr. John Cush RheumNow
2 years 3 months ago
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush RheumNow
2 years 3 months ago
EULAR 2024 Rheumatology Roundup
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
https://t.co/TqEAuk0PGp https://t.co/erRZ3cLxhu
Dr. John Cush RheumNow
2 years 3 months ago
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085
